| Literature DB >> 25190698 |
Mary B Daly, Robert Pilarski, Jennifer E Axilbund, Saundra S Buys, Beth Crawford, Susan Friedman, Judy E Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P Kelly Marcom, Sofia D Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C Voian, Jeffrey N Weitzel, Alison Whelan, Georgia L Wiesner, Mary A Dwyer, Rashmi Kumar.
Abstract
During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/PTEN hamartoma tumor syndrome.Entities:
Mesh：
Year: 2014 PMID： 25190698 DOI： 10.6004/jnccn.2014.0127
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908